This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM).
The name of the study drug involved in this study is:
-Pacritinib (a type of kinase inhibitor)
Age ≥18 years
ECOG performance status ≤2
Clinicopathological diagnosis of Waldenström Macroglobulinemia
constitutional symptoms: recurrent fever, night sweats, fatigue or weight loss
Current history of uncontrolled HIV
Patients with a known history of HIV must have a viral load assessed for eligibility and must be on a stable antiretroviral regimen that can be administered concurrent with pacritinib.
Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below
Hepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (antiHBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before enrollment. Patients who are hepatitis B PCR positive will be excluded.
Shayna Sarosiek, MD
Lead sponsor
Dana-Farber Cancer Institute
Sponsor institution
Sobi, Inc.
Collaborator